Price: $ 1295
BMI View: Despite a challenging pricing and reimbursement situation, BMI still believes the market is attractive in the long term as higher y-o-y growth rates return from 2013/14. In contrast to European markets where manufacturers can expect to achieve higher prices, but with a stagnant growth outlook, Turkey offers strong growth potential if drugmakers are able to accept a price that is considerably below the European average and turn a profit on the low margins available. Headline Expenditure Projections ? Pharmaceuticals: TRY16.39bn (US$9.11bn) in 2012 to TRY17.16bn (US$8.89bn) in 2013; +4.7% in local currency and -2.4% US dollar terms. Local currency forecast unchanged from previous quarter. ? Healthcare: TRY96.98bn (US$53.88bn) in 2012 to TRY109.66bn (US$56.82bn) in 2013; +13.1% in ...
Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/295124.html
No comments:
Post a Comment